Biocept Inc. (BIOCQ) - Net Assets
Based on the latest financial reports, Biocept Inc. (BIOCQ) has net assets worth $290.00K USD as of June 2023. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($22.10 Million) and total liabilities ($21.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read how much debt does Biocept Inc. carry for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $290.00K |
| % of Total Assets | 1.31% |
| Annual Growth Rate | -7.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 79.06 |
Biocept Inc. - Net Assets Trend (2019–2022)
This chart illustrates how Biocept Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore Biocept Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Biocept Inc. (2019–2022)
The table below shows the annual net assets of Biocept Inc. from 2019 to 2022. For live valuation and market cap data, see how much is Biocept Inc. worth.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $8.86 Million | -76.36% |
| 2021-12-31 | $37.48 Million | +58.19% |
| 2020-12-31 | $23.69 Million | +111.53% |
| 2019-12-31 | $11.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biocept Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5272081100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.02% |
| Other Components | $307.30 Million | 3468.35% |
| Total Equity | $8.86 Million | 100.00% |
Biocept Inc. Competitors by Market Cap
The table below lists competitors of Biocept Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ethernity Networks Ltd
LSE:ENET
|
$292.01 |
|
Waldencast Acquisition Corp
NASDAQ:WALDW
|
$292.53 |
|
Future Supply Chain Solutions Limited
NSE:FSC
|
$292.94 |
|
Guna Timur Raya PT
JK:TRUK
|
$316.73 |
|
Jasmine International Public Company Limited
F:JASN
|
$226.62 |
|
Spiritus Mundi PLC
LSE:SPMU
|
$224.94 |
|
Housing Development and Infrastructure Limited
NSE:HDIL
|
$222.65 |
|
Ordinary Fully Paid Deferred Settlement
AU:EDEDA
|
$218.91 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biocept Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 37,480,000 to 8,860,000, a change of -28,620,000 (-76.4%).
- Net loss of 32,087,000 reduced equity.
- New share issuances of 240,000 increased equity.
- Other factors increased equity by 3,227,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-32.09 Million | -362.16% |
| Share Issuances | $240.00K | +2.71% |
| Other Changes | $3.23 Million | +36.42% |
| Total Change | $- | -76.36% |
Book Value vs Market Value Analysis
This analysis compares Biocept Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $162.64 | $0.00 | x |
| 2020-12-31 | $60.00 | $0.00 | x |
| 2021-12-31 | $76.10 | $0.00 | x |
| 2022-12-31 | $15.68 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biocept Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -362.16%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -124.09%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 3.48x
- Recent ROE (-362.16%) is below the historical average (-167.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -224.43% | -454.69% | 0.31x | 1.58x | $-26.26 Million |
| 2020 | -75.16% | -64.84% | 0.58x | 2.00x | $-20.18 Million |
| 2021 | -7.53% | -4.61% | 1.01x | 1.61x | $-6.57 Million |
| 2022 | -362.16% | -124.09% | 0.84x | 3.48x | $-32.97 Million |
Industry Comparison
This section compares Biocept Inc.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $603,097,911
- Average return on equity (ROE) among peers: -221.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biocept Inc. (BIOCQ) | $290.00K | -224.43% | 75.22x | $262.00 |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About Biocept Inc.
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients … Read more